Diasorin SpA (WBO:DIAS) Other Stockholders Equity: €1,698 Mil (As of Dec. 2025)


WBO:DIAS Diasorin SpA WBO:DIAS
74 GF Score
Price €69.68
GF Value €90.06
Valuation Modestly Undervalued
! 6 Warning Signs
View Full Analysis

What is Diasorin SpA Other Stockholders Equity?

Diasorin SpA WBO:DIAS +2.47% 74 Other Stockholders Equity is €1,698 Mil as of Dec. 2025. GuruFocus rates WBO:DIAS with a GF Score™ of 74/100 and a GF Value™ of €90.06 (Modestly Undervalued). The stock has 6 warning signs investors should review.

Diasorin SpA's Other Stockholders Equity for the quarter that ended in Dec. 2025 was €1,698 Mil.

Diasorin SpA's quarterly Other Stockholders Equity declined from Jun. 2025 (€1,607 Mil) to Sep. 2025 (€1,570 Mil) but then increased from Sep. 2025 (€1,570 Mil) to Dec. 2025 (€1,698 Mil).

Diasorin SpA's annual Other Stockholders Equity increased from Dec. 2023 (€1,601 Mil) to Dec. 2024 (€1,790 Mil) but then declined from Dec. 2024 (€1,790 Mil) to Dec. 2025 (€1,698 Mil).

Diasorin SpA Other Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Diasorin SpA's Other Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Diasorin SpA Other Stockholders Equity Chart

Diasorin SpA Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Stockholders Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 246.92 377.19 1,601.46 1,790.49 1,698.07

Diasorin SpA Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,685.90 1,607.38 1,570.00 1,698.07 1,497.00
WBO:DIAS
74GF Score
Diasorin SpA WBO:DIAS
Other Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Diasorin SpA Other Stockholders Equity Calculation

Other Stockholders Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. GuruFocus lists following items in "Total Stockholders Equity" section:
Common Stock
Preferred Stock
Retained Earnings
Accumulated other comprehensive income (loss)
Additional Paid-In Capital
Treasury Stock
Other Stockholders Equity

What does a Other Stockholders Equity of €1,698 Mil mean?
Diasorin SpA (WBO:DIAS) has a Other Stockholders Equity of €1,698 Mil as of Dec. 2025. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Diasorin SpA and its competitors.
Is Diasorin SpA's Other Stockholders Equity too high?
Diasorin SpA's current Other Stockholders Equity is €1,698 Mil. Overall, Diasorin SpA has a GF Score™ of 74/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Diasorin SpA's Other Stockholders Equity compare to TMO and DHR?
Diasorin SpA's Other Stockholders Equity of €1,698 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Stockholders Equity for a Medical Diagnostics & Research company?
A good Other Stockholders Equity depends on the Medical Diagnostics & Research industry context. However, Other Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Stockholders Equity mean?
A high Other Stockholders Equity can signal that a stock is expensive relative to its fundamentals. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Diasorin SpA and its competitors. Diasorin SpA's current Other Stockholders Equity is €1,698 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Diasorin SpA stock overvalued right now?
Based on GuruFocus' analysis, Diasorin SpA (WBO:DIAS) is currently considered Modestly Undervalued. The stock's GF Value™ is €90.06, compared to a current price of €69.68 — trading 22.6% below its estimated fair value. The current Other Stockholders Equity is €1,698 Mil. Diasorin SpA's overall GF Score™ is 74/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Stockholders Equity calculated?
Other Stockholders Equity is calculated from a company's financial statements. For Diasorin SpA (WBO:DIAS), the current Other Stockholders Equity is €1,698 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Diasorin SpA (WBO:DIAS) Overvalued in 2026?

Based on GuruFocus' analysis, Diasorin SpA stock appears to be undervalued. The current stock price of €69.68 is trading 22.6% below its estimated GF Value™ of €90.06. GuruFocus considers Diasorin SpA to be Modestly Undervalued.

Key valuation signals for WBO:DIAS:

  • Other Stockholders Equity: €1,698 Mil
  • GF Value™: €90.06 vs. price of €69.68 (22.6% below fair value)
  • GF Score™: 74/100 with 6 warning signs

No single metric tells the full story. See the WBO:DIAS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Diasorin SpA Business Description

Address Via Crescentino Snc, Saluggia, Vercelli, ITA, 13040
Diasorin develops and manufactures a broad portfolio of in vitro diagnostics for detecting pathogens and sample contamination from the human body, as well as for use in industrial settings, such as food and water contamination testing. The company operates three segments: immunodiagnostics (69% of sales), molecular diagnostics (16%), and licensed technologies (14%). Diasorin was an important manufacturer of covid tests, which boosted its profits during the pandemic, but this segment's importance has decreased over the years, and in 2025, it accounted for only 1% of total sales.
74GF Score

Get the complete analysis for WBO:DIAS

Other Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€69.68
Price
€90.06
GF Value